
WHO Welcomes Signing of Sublicences with 3 Manufacturers to Produce Long-acting Injectable Cabotegravir for HIV Prevention
WHO is pleased to report that three manufacturers have signed licensing agreements with the Medicines Patent Pool (MPP) to develop long-acting injectable cabotegravir (CAB-LA) as pre-exposure prophylaxis (PrEP).